Recent findings revealed that METTL14 exerted an oncogenic function by increasing the expression levels of targets such as MYB and MYC in AML, while SPI downregulated the expression level of MEETL14 (Weng et al., 2018). This evidence concerns the gene MYC and acute myeloid leukemia.